CNBC.com’s Pippa Stevens brings you the most important business news headlines of the day. On today’s show, Meg Tirrell explains why the FDA and CDC called to stop the administration of Johnson & Johnson vaccines after six women developed a rare blood clot disorder. In addition, Kate Rogers is investigating why restaurants have problems recruiting employees when guests return.
FDA advises states to discontinue use of J&J Covid vaccine after rare blood clotting problem strikes 6 women, kills 1
The Food and Drug Administration asked states on Tuesday to temporarily stop the use of Johnson & Johnson’s Covid-19 vaccine “out of an abundance of caution” after six women in the US developed a rare blood clotting disorder that killed one woman and another. in critical condition. state.
“Right now, these side effects appear to be extremely rare,” the FDA said in a joint statement with the Centers for Disease Control and Prevention. “The safety of the COVID-19 vaccine is a top priority for the federal government and we take all reports of health problems following vaccination with COVID-19 very seriously.”
All six cases occurred in women aged 18 to 48, with symptoms developing six to 13 days after receiving the injection. Doctors usually treat that type of blood clot with heparin, but health authorities noted that it could be dangerous in this case and recommended a different treatment.
States rush to replace J&J vaccine appointments after FDA recommends hiatus
More than two dozen states took steps on Tuesday to stop Johnson & Johnson coronavirus vaccine vaccinations shortly after the Food and Drug Administration recommended halting its use after reports that some women were developing a rare blood clotting disorder.
States, such as the FDA and the Centers for Disease Control and Prevention, stressed that they were acting out of an abundance of caution, as more than 6.8 million doses of the J&J vaccine were injected and only six of the cases of blood clotting have taken place so far. reported.
J&J said in a statement that “no clear causal relationship” has been established between the rare type of blood clots and the vaccine, adding that it is working closely with regulators to review the data.
Bitcoin hits a new all-time high above $ 63,000 ahead of Coinbase’s debut
Bitcoin soared to a new high of more than $ 63,000 on Tuesday as investors awaited the highly anticipated stock market debut of cryptocurrency exchange Coinbase.
Bitcoin’s price soared to $ 63,236, according to Coin Metrics data, before declining slightly to around $ 62,877. It was last up about 5% in the last 24 hours. Ether, the second most valuable digital currency after bitcoin, also set a new record, rising to $ 2,230.
Coinbase will go public on Wednesday on a direct listing that could value the company at a whopping $ 100 billion – more than major trading platform operators like Intercontinental Exchange, which owns the New York Stock Exchange. Crypto investors hail the company’s stock market debut as a significant milestone for the industry after years of skepticism from Wall Street and regulators.